We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Highlights Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients DMX-200 was found to be generally safe and well-tolerated in FSGS patients 86% of patients...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0375 | -7.65306122449 | 0.49 | 0.555 | 0.4475 | 5360924 | 0.50271419 | DE |
4 | 0.1425 | 45.9677419355 | 0.31 | 0.555 | 0.305 | 4587603 | 0.47329347 | DE |
12 | 0.0275 | 6.47058823529 | 0.425 | 0.555 | 0.3 | 2334916 | 0.42633662 | DE |
26 | -0.1025 | -18.4684684685 | 0.555 | 0.58 | 0.3 | 2559590 | 0.42789772 | DE |
52 | 0.2575 | 132.051282051 | 0.195 | 0.665 | 0.16 | 3628769 | 0.39438024 | DE |
156 | 0.1875 | 70.7547169811 | 0.265 | 0.665 | 0.052 | 1843713 | 0.31346025 | DE |
260 | 0.3125 | 223.214285714 | 0.14 | 0.78 | 0.052 | 1509708 | 0.31281903 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions